Latest research

The MS Trust is delighted that ozanimod (Zeposia) has been approved in Scotland for people with active relapsing remitting multiple sclerosis.

There is more to exercise than physical fitness. This review looks at recent research which shows how exercise has a direct beneficial effect on brain repair processes.

Following our last interview on the subject of the Covid-19 vaccine and people with MS, we received a lot of follow up questions. To answer some of these, we spoke once again to Professor Alasdair Coles, Consultant Neurologist at Addenbrooke’s hospital.

The MS Trust is very disappointed that NICE does not recommend ozanimod (Zeposia) as an NHS treatment in England and Wales.

A potential treatment for multiple sclerosis uses mRNA technology, similar to two of the Covid-19 vaccines. Find out more about this research.

In this study, researchers compared daytime sleepiness while driving in people with and without MS.

Most people with MS will have heard of demyelination but perhaps not remyelination. We spoke with Dr Nick Cunniffe, who has been involved in some of the recent remyelination research, to find out more.

There's been a lot of interest around the new Covid-19 vaccines and how they might affect people with multiple sclerosis (MS). We've collected some common questions and answers from the MS Trust Enquiry Service this week to share with you.

The MHRA has approved a Covid-19 vaccine, and the government and NHS are preparing to deliver a mass vaccination programme in the UK. Where do people with multiple sclerosis (MS) fit into the priority list?

We speak to a neurologist about whether a future Covid-19 vaccine would be safe and effective for people with MS.

An update from the this ECTRIMS and ACTRIMS which is the largest annual MS research conference. 

The MS Trust is delighted that siponimod (Mayzent) has also been approved by NICE in England and Wales.